Apalutamide as a therapeutic option in case of local failure in the nmCRPC

Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive cancer. The paper describes case patient diagnosed with long-term course disease. was stage 18 years after primary treatment. Systemic apalutamide recommended. Initially, carried out as part extended access to program from March 2022 B.56 drug program. study presents effectiveness safety therapy in 12-month follow-up period discusses controversial aspects patient's previous treatments.